Drug Trial Radar · NCT00944424
Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca
Last checked: Nov 20, 2026Latest source record: Dec 13, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
260
Planned (sponsor's estimate)
Start
Jul 2009
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- King Faisal Specialist Hospital & Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized phase III trial to determine the effectiveness of High dose versus Standard dose of Vitamin D2 (Ergocalciferol) given with Docetaxel in patients with metastatic breast cancer
Conditions
- Breast Cancer
Interventions
Docetaxel + High dose Vitamin D2Drug
Docetaxel + High dose Vitamin D2
Docetaxel + Standard dose Vitamin D2Drug
Docetaxel + Standard dose Vitamin D2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to progression is from the start of Docetaxel to disease progression. Patients who have not progressed at the time of study completion or who are lost to follow-up are censored at the last Vitamin D administration date.Time frame: 1 year
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Kuwait Cancer Center
Kuwait City, Kuwait · Not yet recruiting
King Abdulaziz Hospital and Oncology Center
Jeddah, Saudi Arabia · Not yet recruiting
King Abdulaziz Medical City
Riyadh, Saudi Arabia · Not yet recruiting
King Fahad Medical City
Riyadh, Saudi Arabia · Not yet recruiting
King Faisal Specialist Hospital & Research Center
Riyadh, Central, Saudi Arabia · Recruiting
Tawam Hospital
Al Ain City, United Arab Emirates · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.